Category Archives: Data Exclusivity

Canadian generic drugmakers find fault with USMCA

Source: Pharmaletter 3rd Oct 2018, New Delhi The pharmaceutical intellectual property aspects of the United States-Mexico-Canada Agreement (USMCA), which was agreed on Monday to replace the former North American Free Trade Agreement (NAFTA) accord, have come in for criticism from the … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, USMCA | Leave a comment

Wrapping Up 2017 – some noteworthy medicines law and policy events.

By  Ellen ‘t Hoen, Medicines Law & Policy | December 31, 2017 2017 was a significant year for access to medicines and other medicines policy related events. Here are a few highlights of the last 12 months. January 2017 kicked off with … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, ISDS, TRIPS, Uncategorized | Leave a comment

Rethinking IP in the TPP: Canadian Government Plays Key Role in Suspending Unbalanced Patent and Copyright Rules

Source: http://www.michaelgeist.ca/2017/11/rethinking-ip-in-the-tpp/ Years of disappointment in trade negotiations have left many Canadian intellectual property watchers hoping for the best, but expecting the worst when it comes to the IP provisions in trade deals. In earlier talks, Canadian negotiators would often advocate … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent Term Extension, TPP, TRIPS, TRIPS plus, Uncategorized | Leave a comment

Time for costly medicine monopolies to go from TPP trade talks

Source: Conversation.com |November 9, 2017 Negotiators from 11 countries have been racing to resurrect the near-dead Trans-Pacific Partnership Agreement before the Asia-Pacific Economic Cooperation (APEC) summit this weekend. The latest plan to get the controversial trade deal up and running … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent, TPP, Uncategorized | Leave a comment

India to oppose anti-generics proposals at RCEP meet

Source: LiveMint India stands firm in opposing proposals that could hinder global access to affordable generic drugs and life-saving vaccines South Korea and Japan have been pushing for proposals to extend drug and vaccine patent terms, a move that is … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

Global access to affordable medicines should not be restricted

MSF has witnessed the negative impact of monopoly pricing on life-saving medicines and vaccines in its medical projects all over the world. Courtesy- ajp.com.au As 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) agreement meet this week in Incheon, … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

India Will Not Cross Red Lines on Generic Drugs in RCEP, but Stay Vigilant, Say Officials

Source: The Wire Healthcare watchers are calling on India to resist the free trade agreement’s provisions which could compromise India’s ability to keep supplying cheaper generic drugs to the world. Hundreds of government officials and activists huddle separately in South … Continue reading

Posted in Data Exclusivity, Generics, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment